Contact Information
Company Information
Company
Allogene Therapeutics
Technologies
Outlook
Microsoft Office 365
Google Font API
Gravity Forms
Mobile Friendly
Google Tag Manager
Facebook Custom Audiences
Nginx
Open AdStream (Appnexus)
Facebook Widget
Facebook Login (Connect)
Vimeo
Google Analytics
Linkedin Marketing Solutions
WordPress.org
Render
Micro
IoT
Remote
AI
Keywords
oncology
cancer
biotechnology
immunotherapy
car t
autoimmune
biotechnology: biological products (no diagnostic substances)
health care
allocar t
cell therapy
autoimmune disease
cancer treatment
chimeric antigen receptor
off-the-shelf
investigational products
multiplex gene-editing
lymphodepletion
clinical trials
phase 1 trial
phase 2 trial
fda designation
therapeutic advancements
allogeneic car t
manufacturing capabilities
drug development
patient access
innovative medicines
cancer immunotherapy
treatment optimization
commercialization strategy
research & development
preclinical data
cemacabtagene ansegedleucel
allo-316
allo-329
dual car t
gene editing
clinical-stage company
management team
investment opportunities
financial results
stock information
corporate governance
scientific publications
healthcare conferences
biopharmaceutical innovations
on-demand therapy
publications
regenerative medicine
disease targets
therapeutic candidates
clinical effectiveness
patient-centric approach
pipeline strategy
collaborative research
business development
allogeneic car t cell therapy
off-the-shelf treatments
autoimmune diseases
hematological malignancies
solid tumors
multiplex gene editing
proprietary lymphodepletion platform
innovative biotechnology
patient accessibility
scalable manufacturing
fda fast track designation
diversity & inclusion
healthcare providers
oncologists
biopharmaceutical industry
patient outcomes
hospital & health care
health
wellness & fitness
b2b
Get Full Contact Details
Subscribe to reveal email addresses and export contacts.
View Plans